Exam (elaborations)
BCPS Exam 2024
- Course
- Institution
Exam of 8 pages for the course BCPS at BCPS (BCPS Exam 2024)
[Show more]
Seller
Follow
tutorsection1
Reviews received
Content preview
BCPS Exam 2024/2025 Questions and Answers (GradedA)
____ is the most appropriate answer because there are no drug-drug interactions or
contraindications / cautions in HIV - ANSWER Bictegravir
n patients with persistent neutropenic fever despite anti-pseudomonal coverage,
what should be considered? - ANSWER empiric antifungal therapy should be
considered after 4 - 10 days
electrocautery - ANSWER Which of the following therapies is most likely to result in
a resolution rate which approaches 100% in patients w/ external anogenital warts.?
preferred therapy for CMV retinitis? - ANSWER Ganciclovir intravitreal injections plus
valganciclovir oral
bacterial vaginosis recommended treatment - ANSWER clindamycin or
metronidazole
(i.e. Clindamycin 300 mg orally twice daily for 7 days)
recommended treatment regimen for pelvic inflammatory disease - ANSWER
Ceftriaxone 250 mg intramuscularly x 1 dose plus doxycycline 100 mg orally twice
daily for 14 days
vulvovaginal candidiasis teeatment - ANSWER Clindamycin cream 2%, 5 g
intravaginally at bedtime for 7 days
MedWatch - ANSWER preferred route for healthcare professionals and patients to
report suspected adverse events to the FDA
FDA Form 3500A - ANSWER mechanism for reporting suspected adverse events,
but is reserved for use by user-facilities, importers, distributors, and manufacturers
-reporting errors related to vaccines - ANSWER ISMP VERP and VAERS
viral rhinosinusitis sx duration - ANSWER -peak at 3 days and may persist longer
than 14 days but usually decreases in severity by 10 days
-watchful waiting is recommended to avoid overuse of antibiotics as episodes are
often self-limited
Malignant external otitis treatment - ANSWER - predominantly caused by
Pseudomonas aeruginosa
-antipseudomonal antimicrobials are considered the mainstay of therapy.
, Fidaxomicin - ANSWER -associated with decreased recurrence of Clostridioides
difficile likely owing to its narrow spectrum and minimal effect on normal colonic flora
duration of initial therapy for CDI? - ANSWER 10 days with oral vancomycin or
fidaxomicin
MRSA PCR - ANSWER -well-recognized tool for antimicrobial de-escalation as part
of stewardship initiatives given the high negative predictive value
MRSA nasal culture - ANSWER -used for surveillance and is not employed as a
stewardship tool
Procalcitonin - ANSWER -useful in differentiating between viral and bacterial
etiologies
-chronic kidney disease may cause an artificially high level leading to questionable
interpretation and potential continuation of inappropriate antimicrobials
Asymptomatic candiduria - ANSWER -common among hospitalized patients with an
indwelling urinary catheter and treatment is nt is not warranted
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF) -
ANSWER Elvitegravir is only available in single-tablet regimen form; either as
EVG/c/FTC/TAF or EVG/c/FTC/TDF. Therefore, it is not possible to stock the single
agents and "break up" the patient's regimen
Waterfall plot - ANSWER -Waterfall plot is ideal to represent secondary objectives.
BRAF Mutation - ANSWER BRAF mutation confers resistance to EGFR inhibitors;
Anti-EGFR therapies should be avoided in KRAS WT and BRAF mutant mCRC
unless given in combination with BRAF inhibitor
Palbociclib - ANSWER -FDA approval for male breast cancer in combination with an
aromatase inhibitor or fulvestrant for men with hormone receptor-positive (HR+),
human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic
breast cancer
Atezolizumab combined with nab-paclitaxel - ANSWER -in breast CA is based on the
PD-L1 expression on tumor-infiltrating immune cells
Olaparib - ANSWER -Breast cancer
-metastatic,
-HER2-negative -germline BRCA-mutated (gBRCAm)
Tvec indication - ANSWER -second-line setting
- patients with skin involvement
-not metastatic
platinum-sensitive disease - ANSWER =/> 6 months
<6 months - ANSWER platinum refractory
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller tutorsection1. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $17.99. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
81298 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now